← Return to Any early (less than 5yrs) local recurrence of early stage IDC?

Comment receiving replies

Thank you Callallou for your reply! I am perplexed about the oncotype info, since you report you've been informed it applies to local recurrence along with distant, so I just wrote the company again and received a rapid reply:
''Your Oncotype DX recurrence score predicts the distant recurrence risk at 9 years with endocrine therapy alone, as well as your estimated chemotherapy benefit. Unfortunately, recurrent tumors were not validated in the Oncotype clinical studies therefore we are unable to perform testing on recurrent tumors since they are outside of our criteria.

We did not observe local recurrence risk in our validation studies, only distant recurrence risk. We are only validated to report out information on patient's distant recurrence risk.''

I also asked what features in the genomic assay were associated with the distant risk, but did not receive a reply about that. I realize this is probably not of great interest to others, but since I am recovering from this recent local recurrence, I am just really hoping I remain protected from the a distant recurrence given my relatively safe, low Oncotype score.

Again, thanks for your input!

Jump to this post

Replies to "Thank you Callallou for your reply! I am perplexed about the oncotype info, since you report..."

Hmmm. I can understand if Oncotype's reply is differentiating between 'spread' of an original cancer versus a later, new cancer deemed a 'recurrence' by virtue of chronology, though conceptually the same cancer just not fully destroyed by treatment or surgery. That could be considered, incorrectly, a 'local' recurrence?

I talked to a senior science guy at the company and when he used the word 'local' he meant in the same general area, but not necessarily the same site. And said the risk percentage applied to 'loco-regional' recurrence. To me, the reply you received raises more questions, starting with exactly what they're calling 'distant.' Would cancer in the opposite breast be 'distant'?
The terms are important.

I'll try to talk to the same senior person at the company who clarified some stuff before for me. I have some lingering questions anyway, including how to get a copy of which genes were assayed and if there were any mutations found and what the Recurrence Score means. One thing that he told me, which I found interesting, is that the test result is based strictly on what the lab sees. The results aren't further tweaked for any demographic variables or other risk assumptions.

If I get a clearer answer, if it's OK with you, I'll private message you to prevent skewing off topic for those not interested.